Compare BridgeBio Pharma Inc (BBIO) vs TeraWulf Inc (WULF) Price & Performance

BridgeBio Pharma IncTrade

TeraWulf IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs TeraWulf Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while TeraWulf Inc trades at $17.41 (market cap $8.35B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals.

	BBIO	WULF
Market Cap	$16.36B	$8.35B
Sector	Health	Technology
52-Week High	$90.17	$28.98
52-Week Low	$47.29	$5.24
Enterprise Value	$18.14B	$10.97B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

No Aura AI signal available yet.

TeraWulf Inc

TeraWulf (WULF) trades at $17.08, down 3.04% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $165M but a significant net loss of -$1.9B, reflecting a profit margin of -1,179.95%. Despite negative profitability metrics, all 14 analysts maintain Buy ratings with a $38 consensus price target, citing growth potential from AI infrastructure expansion including a major Anthropic lease.

The stock presents a high-risk, high-reward opportunity with strong Wall Street conviction despite fundamental challenges. Key catalysts include the AI pivot and capacity expansion, but investors face substantial execution risks, capital requirements, and ongoing losses that could pressure the stock near-term.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BBIO

BridgeBio beats Q2 estimates, confirms $1B+ 2026 sales goal and plans three product launches by 2027.Seeking Alpha · 21 hours agoBullish View details →

WULF

Neocloud stocks rise as NVIDIA-led $500B AI financing plan boosts data center buildout prospects24/7 Wall Street · 21 hours agoBullish Riot Platforms shares jump 17% on $9.1B AI data center lease with Anthropic.24/7 Wall Street · 1 day agoBullish TeraWulf leads AI infrastructure stocks in 2026 with a 40.82% gain, driven by a major Anthropic lease deal.24/7 Wall Street · 1 day agoBullish View details →

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

About TeraWulf Inc

TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.